ArticleJournal of veterinary internal medicine
Brain Atrophy in Dogs With Meningoencephalitis of Unknown Origin.
Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cerebrospinal fluid markers and magnetic resonance imaging lesion volume predicting relapse in canine meningoencephalitis of unknown origin.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInformation regarding repeat magnetic resonance imaging (MRI) findings in dogs with meningoencephalitis of unknown origin (MUO) is sparse and it is unknown whether brain atrophy occurs.
objectivesTo determine whether brain atrophy occurs in MUO and evaluate if there is an association between atrophy and survival or relapse. ANIMALS: Twenty-three dogs diagnosed with MUO that underwent MRI of the brain on two occasions at least six months apart.
methodsRetrospective study. Interthalamic adhesion thickness to brain height ratio (ITr), lateral ventricle to brain height ratio (LVr), interthalamic adhesion thickness/brain height to lateral ventricle/brain height (ITr/LVr), bicaudate ratio (BCR) and total parenchymal brain volume (TPBV) were measured on both MRI studies and compared.
resultsThirteen dogs relapsed and four died during the study period. Median time between MRIs was 12 months, and only one imaging study (1/23) was considered normal on the second scan. All MRI variables measured significantly changed between imaging studies, but only higher TPBV was associated with increased survival (OR = 1.59, CI = 1.006-2.51, p = 0.047); no variables were found to be associated with relapse. New lesions were identified in six dogs (four of which also showed contrast enhancing lesions), with 5/6 of these dogs subsequently relapsing. CONCLUSIONS AND CLINICAL IMPORTANCE: Brain atrophy likely occurs in dogs with MUO and is associated with worse outcomes. Clinical relapse might be likely in dogs with new or contrast-enhancing lesions on repeat MRI, so more aggressive treatment should be considered in these dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.